These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8258993)

  • 21. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
    Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
    J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
    Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
    J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of human T cells with NK cell markers by staphylococcal enterotoxin A via IL-12 but not via IL-18.
    Ami K; Ohkawa T; Koike Y; Sato K; Habu Y; Iwai T; Seki S; Hiraide H
    Clin Exp Immunol; 2002 Jun; 128(3):453-9. PubMed ID: 12109440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
    Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
    Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
    Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Immunology; 1997 Jan; 90(1):74-80. PubMed ID: 9038715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
    Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
    Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma.
    Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN
    Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically engineered superantigens as tolerable antitumor agents.
    Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR.
    Antonsson P; Wingren AG; Hansson J; Kalland T; Varga M; Dohlsten M
    J Immunol; 1997 May; 158(9):4245-51. PubMed ID: 9126986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A.
    Sundstedt A; Grundström S; Dohlsten M
    Immunology; 1998 Sep; 95(1):76-82. PubMed ID: 9767460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
    Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
    Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
    Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
    Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
    Lamphear JG; Stevens KR; Rich RR
    J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superantigens anergize cytokine production but not cytotoxicity in vivo.
    Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T
    Immunology; 1994 May; 82(1):117-25. PubMed ID: 7913912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells.
    Hansson J; Ericsson PO; Dohlsten M; Sjögren HO; Kalland T; Hedlund G
    Immunol Lett; 1992 Dec; 34(3):229-36. PubMed ID: 1487309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superantigen-induced lysis of melanoma cells.
    Krull F; Holzer U; Ihle J; Bethge W; Fierlbeck G; Kalland T; Dohlsten M; Niethammer D; Dannecker GE
    Melanoma Res; 1997 Jun; 7(3):214-22. PubMed ID: 9195560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
    Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
    J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma.
    Nielsen SE; Zeuthen J; Lund B; Persson B; Alenfall J; Hansen HH
    J Immunother; 2000 Jan; 23(1):146-53. PubMed ID: 10687147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.